MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Exagen Net Debt 2011-2026 | XGN
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Exagen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.73 M | -1.12 M | -16.3 M | -32.6 M | -72 M | -4.13 M | -46 M | 11.5 M | 7.6 M | - | 23.4 M | 13.9 M | 1.17 M | -150 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.4 M | -72 M | -9.49 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Co-Diagnostics
CODX
|
-10.6 M | $ 1.63 | -1.21 % | $ 2.17 M |  USA |
 |
Agilent Technologies
A
|
1.24 B | $ 114.87 | -0.65 % | $ 34.9 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
-108 M | $ 24.7 | -1.12 % | $ 686 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M |  Israel |
 |
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
CareDx, Inc
CDNA
|
-39.2 M | $ 21.91 | 0.27 % | $ 1.17 B | USA |
 |
Illumina
ILMN
|
-494 M | $ 126.92 | -1.24 % | $ 20.2 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-53.3 M | $ 15.3 | -1.92 % | $ 463 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
213 M | $ 83.55 | -0.67 % | $ 5.64 B | USA |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
1.98 B | $ 166.79 | -2.59 % | $ 8.27 B | USA |
 |
National Research Corporation
NRC
|
71.3 M | $ 16.84 | -1.58 % | $ 377 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
 |
Guardant Health
GH
|
1.15 B | $ 83.09 | -6.11 % | $ 10.4 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 27.12 | -1.53 % | $ 20 B |  Niderland |
 |
Precipio
PRPO
|
-2.19 M | $ 31.75 | 3.42 % | $ 51 M | USA |
 |
Personalis
PSNL
|
-48.8 M | $ 5.5 | -7.72 % | $ 326 M | USA |
 |
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.93 | - | $ 8.54 M | USA |
 |
Senseonics Holdings
SENS
|
-4.15 M | $ 7.18 | -1.24 % | $ 300 M | USA |
 |
Medpace Holdings
MEDP
|
-360 M | $ 409.65 | -2.78 % | $ 11.8 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | Niderland |
 |
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | Israel |
 |
Biomerica
BMRA
|
-1.94 M | $ 2.19 | 0.46 % | $ 5.03 M | USA |
 |
Thermo Fisher Scientific
TMO
|
29.6 B | $ 470.22 | 0.47 % | $ 177 B | USA |
 |
ICON Public Limited Company
ICLR
|
4.63 B | $ 102.49 | -0.7 % | $ 8.45 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 259.57 | -1.47 % | $ 21.6 B | USA |
 |
Trinity Biotech plc
TRIB
|
55.4 M | $ 0.61 | -4.93 % | $ 61.9 M | Irlanda |
 |
Neogen Corporation
NEOG
|
751 M | $ 9.34 | -1.16 % | $ 2.03 B | USA |
 |
Celcuity
CELC
|
-28.1 M | $ 120.07 | -4.46 % | $ 5.61 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-107 M | $ 59.15 | -3.03 % | $ 3.54 B | USA |
 |
NeoGenomics
NEO
|
187 M | $ 9.02 | 4.76 % | $ 1.16 B | USA |
 |
Myriad Genetics
MYGN
|
115 M | $ 4.84 | 0.21 % | $ 448 M | USA |
 |
Natera
NTRA
|
-177 M | $ 200.17 | -2.06 % | $ 19.7 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 195.05 | -0.8 % | $ 21.7 B | USA |
 |
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | USA |
 |
OpGen
OPGN
|
711 K | - | -16.95 % | $ 1.54 M | USA |